PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
1.81%
Growth of 1.81% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
-7.28%
Cost reduction while Drug Manufacturers - Specialty & Generic median is -4.27%. Seth Klarman would investigate competitive advantage potential.
23.28%
Growth of 23.28% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
21.09%
Margin change of 21.09% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
135.68%
R&D growth while Drug Manufacturers - Specialty & Generic reduces spending. Peter Lynch would examine strategic differences.
0.96%
G&A change of 0.96% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
7.45%
Marketing expense change of 7.45% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-70.19%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
5.07%
Operating expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
-3.48%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is -5.12%. Seth Klarman would investigate advantages.
63.11%
Interest expense change of 63.11% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
13.90%
D&A change of 13.90% versus flat Drug Manufacturers - Specialty & Generic D&A. Walter Schloss would verify adequacy.
22.10%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.50%. Joel Greenblatt would investigate advantages.
-43.85%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 4.08%. Seth Klarman would investigate causes.
119.76%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.80%. Joel Greenblatt would investigate advantages.
119.41%
Operating margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 12.55%. Joel Greenblatt would investigate advantages.
-65.63%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
12.44%
Pre-tax income growth near Drug Manufacturers - Specialty & Generic median of 11.60%. Charlie Munger would verify industry dynamics.
10.44%
Pre-tax margin growth near Drug Manufacturers - Specialty & Generic median of 10.95%. Charlie Munger would verify industry dynamics.
495.97%
Tax expense change of 495.97% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
-0.34%
Net income decline while Drug Manufacturers - Specialty & Generic median is 3.60%. Seth Klarman would investigate causes.
-2.11%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
5.93%
EPS growth near Drug Manufacturers - Specialty & Generic median of 5.60%. Charlie Munger would verify industry dynamics.
7.76%
Diluted EPS growth 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 5.68%. Mohnish Pabrai would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.